Recombinant Human PSGL-1/CD162

Recombinant Human PSGL-1/CD162  (CU84)

 

产品说明(Description)

Recombinant Human P-selectin Glycoprotein Ligand 1 is produced by our Mammalian expression system and the target gene encoding Thr42-Gly295 is expressed with a Fc tag at the C-terminus. 

Accession #: Q14242

Known as: P-selectin glycoprotein ligand 1; PSGL-1; Selectin P ligand; CD162; SELPLG 

 

制剂（Formulation）

Lyophilized from a 0.2 μm filtered solution of 20mM Tris,150mM NaCl,pH8.0.

 

质量控制（Quality Control） 

Purity:            Greater than 95% as determined by reducing SDS-PAGE.    

Endotoxin:    Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test.

 

复溶（Reconstitution）

Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.    

 

保存（Storage）

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.

Reconstituted protein solution can be stored at 4-7°C for 2-7 days.

Aliquots of reconstituted samples are stable at < -20°C for 3 months.     

 

背景（Background）

PSGL-1 (CD162), is a mucintype glycoprotein that plays a key role in leukocyte adhesion. Human PSGL-1 cDNA encodes 412 amino acids (aa). It expressed on neutrophils, monocytes and most lymphocytes. The mature PSGL-1 (aa 42-412) is expressed as a disulfide-linked homodimer that signals intracellularly and promotes integrin activation. PSGL-1 is found on virtually all leukocytes, dendritic cells, platelets, and some endothelial cells. It is primarily responsible for early events in extravasation, especially rolling adhesion of leukocytes to vascular endothelium. Through high affinity, This SLe(x)-type proteoglycanPGSL-1 calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation.

 

电泳(SDS-PAGE)

 

参考文献（Reference)

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma[J]. Cinzia Federico. et al. nature communications. 2020.

 

FOR RESEARCH USE ONLY